Role for protease activity in visceral pain in irritable bowel syndrome by Cenac, N . et al.
Research article
636	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 117	 	 	 Number 3	 	 	 March 2007
Role for protease activity in visceral pain  
in irritable bowel syndrome
Nicolas Cenac,1 Christopher N. Andrews,2 Marinella Holzhausen,1 Kevin Chapman,1  
Graeme Cottrell,3 Patricia Andrade-Gordon,4 Martin Steinhoff,5 Giovanni Barbara,6  
Paul Beck,2 Nigel W. Bunnett,3 Keith A. Sharkey,7 Jose Geraldo P. Ferraz,2  
Eldon Shaffer,2 and Nathalie Vergnolle1
1Department of Pharmacology and Therapeutics and 2Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, 
Canada. 3Departments of Surgery and Physiology, UCSF, San Francisco, California, USA. 4R.W. Johnson Pharmaceutical Research Institute, Spring House, 
Pennsylvania, USA. 5Department of Dermatology and Interdisciplinary Center for Clinical Research (IZKF) Münster, University of Münster, Münster, Germany. 
6Departments of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy. 7Department of Physiology and Biophysics,  
Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Mediators	involved	in	the	generation	of	symptoms	in	patients	with	irritable	bowel	syndrome	(IBS)	are	poorly	
understood.	Here	we	show	that	colonic	biopsy	samples	from	IBS	patients	release	increased	levels	of	proteo-
lytic	activity	(arginine	cleavage)	compared	to	asymptomatic	controls.	This	was	dependent	on	the	activation	of	
NF-κB.	In	addition,	increased	proteolytic	activity	was	measured	in	vivo,	in	colonic	washes	from	IBS	compared	
with	control	patients.	Trypsin	and	tryptase	expression	and	release	were	increased	in	colonic	biopsies	from	
IBS	patients	compared	with	control	subjects.	Biopsies	from	IBS	patients	(but	not	controls)	released	mediators	
that	sensitized	murine	sensory	neurons	in	culture.	Sensitization	was	prevented	by	a	serine	protease	inhibi-
tor	and	was	absent	in	neurons	lacking	functional	protease-activated	receptor–2	(PAR2).	Supernatants	from	
colonic	biopsies	of	IBS	patients,	but	not	controls,	also	caused	somatic	and	visceral	hyperalgesia	and	allodynia	
in	mice,	when	administered	into	the	colon.	These	pronociceptive	effects	were	inhibited	by	serine	protease	
inhibitors	and	a	PAR2	antagonist	and	were	absent	in	PAR2-deficient	mice.	Our	study	establishes	that	proteases	
are	released	in	IBS	and	that	they	can	directly	stimulate	sensory	neurons	and	generate	hypersensitivity	symp-
toms	through	the	activation	of	PAR2.
Introduction
Irritable bowel syndrome (IBS) is one of the most common gas-
trointestinal disorders, afflicting 10%–15% of the population in 
developed countries (1, 2). Considered a functional bowel disorder, 
IBS is characterized by abdominal discomfort and pain, associated 
with altered bowel function. IBS bowel symptoms may be char-
acterized by a predominance of constipation (IBS–C) or diarrhea 
(IBS–D) or by alternating constipation and diarrhea (IBS–D/C). 
The notion of “functional” comes from an apparent absence of 
findings supporting an organic basis, since there are no biochemi-
cal, histopathological, or diagnostic imaging criteria yet charac-
terized that define the syndrome. Accordingly, stress or affective 
disorders were long assumed to constitute the key mechanisms 
in the development of IBS (3, 4). Microscopic inflammation has 
recently been proposed to be associated with the development of 
IBS symptoms in some patients (5–8). A history of a gastrointes-
tinal infectious episode is also associated with the development 
of IBS in 18% of these patients (9). IBS can also appear in patients 
with inflammatory bowel disease (IBD) who are in remission (10). 
A unifying hypothesis for the generation of symptoms of IBS 
incorporates a central component (psychological factors), togeth-
er with peripheral organ dysfunction (motility disorders, visceral 
hypersensitivity), possibly aggravated by microscopic inflamma-
tion and/or previous intestinal infection. Most IBS patients expe-
rience underlying visceral hyperalgesia, as measured in studies in 
which a balloon catheter inserted into the rectum was inflated and 
provoked an increased nociceptive response (hyperalgesia) and a 
decreased nociceptive threshold (allodynia) (11).
A major obstacle to the effective treatment of IBS is that the 
mediators of symptoms such as abdominal pain and their mech-
anisms of action are unknown. We sought to determine whether 
mediators released by colonic tissues from IBS patients can signal 
to sensory neurons and reproduce the hypersensitivity symptoms 
in animals. We focused our attention on proteases and their recep-
tors, since they have been shown to cause visceral hyperalgesia in 
animal models (12, 13). Our results show that: (a) biopsies from 
IBS patients release elevated proteolytic activity compared with 
those from control patients; (b) this proteolytic activity can signal 
to sensory neurons through a mechanism involving the activation 
of protease-activated receptor–2 (PAR2); and (c) proteolytic activity 
released from IBS patient tissues, when introduced into the colon of 
mice, causes hypersensitivity symptoms (hyperalgesia and allodynia) 
through a PAR2-dependent mechanism. The present study provides 
evidence for a crucial role for proteases released by colonic tissues of 
IBS patients as mediators that generate hypersensitivity symptoms.
Results
Colonic biopsies from IBS and IBD patients release proteolytic activity. 
Colonic tissue biopsies incubated in culture medium for 1 hour 
released proteolytic activity that cleaves at an arginine site, hydro-
lyzing the substrate tert-butyloxycarbonyl-Gln-Ala-Arg-7-amino-
4-methycoumarin (tert-butyloxycarbonyl-Gln-Ala-AMC) (Figure 
1, A and B). Proteolytic activity released from IBS and IBD patient 
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biopsies was, respectively, 2- to 3-fold and 6-fold higher than the 
activity in control patient samples. The serine protease inhibitor 
FUT-175 completely inhibited activity released from IBS and con-
trol biopsies (Figure 1, A and B). Similar levels of proteolytic activ-
ity were observed in supernatants of biopsies taken either from the 
ascending colon or the rectum of IBS patients (Figure 1, A and B). 
Incubation of with the NF-κB inhibitor BAY 11-7085 (14) signifi-
cantly reduced proteolytic activity released from IBS but not con-
trol biopsies (Figure 1, A and B). The levels of proteolytic activity 
detected in luminal washes of IBS patients were 5-fold higher than 
those detected in luminal washes of control patients (Figure 1C).
Trypsin and tryptase levels are increased in colonic biopsies from IBS 
patients, but mast cells numbers are not elevated. Tryptase and trypsin 
mRNA levels were quantified in colonic biopsies by semiquantitative 
RT-PCR (Figure 2A). A significant increase in tryptase and trypsin 
mRNA expression was observed in tissues from IBS patients com-
pared with healthy controls, with a 1.8- to 2-fold increase for trypt-
ase and a 2.2- to 2.8-fold increase for trypsin (Figure 2A). Similar 
increases in tryptase and trypsin mRNA expression were observed 
whether samples were taken from the rectum or ascending colon in 
IBS patients. Tryptase and trypsin proteins were released by biop-
sies from IBS and control patients, as detected by Western blotting. 
Densitometric analysis indicated that trypsin levels were 1.6- to 
2-fold and tryptase levels 1.8-fold higher in IBS biopsy superna-
tants than in controls (Figure 2B). In IBD patients, the profile of 
proteases released appears to be different from that in IBS patients. 
The level of trypsin protein released by IBD patient biopsies com-
pared with control biopsies was not significantly increased. Only 
tryptase protein levels were higher, by 2-fold, in IBD compared with 
control biopsy supernatants (Figure 2B). 
Mast cells are important cellular sources of proteolytic enzymes 
including tryptase and tryptic-like enzymes (15–17). We therefore 
assessed the expression of tryptase immunoreactivity and the 
number of mast cells in the biopsy samples. Tryptase was mostly 
localized to cells found throughout the lamina propria (Figure 3) 
and around the base of rectal mucosal crypts. Based on their size 
and distribution, these cells are likely to be mast cells (17). Two 
other much smaller populations of cells were observed in these 
samples. Some cells (e.g., Figure 3C) had obvious processes at the 
apical and/or basal poles, and often these cells displayed intense 
immunoreactivity compared with neighboring cells. Occasional 
tryptase-immunoreactive cells were found in the epithelium 
of both control and IBS patients; these had the appearance of 
enteroendocrine cells (Figure 3D). No differences were observed 
between any of the cell populations in IBS and control patients 
with respect to either the density of cells or intensity of immuno-
reactivity (Figure 3G). As noted in Methods, tryptase immunore-
activity was found in some obviously degranulating cells. These 
cells were observed in both patient groups, and no obvious differ-
ences were noted, but these cells were not readily counted because 
of the diffuse nature of the immunoreactivity.
We also investigated the presence of mast cells using Alcian blue 
staining in the lamina propria of biopsy samples from IBS (n = 15) 
and control patients (n = 7). In IBS patient biopsies, there were no 
significant differences in the number of mast cells in the ascending 
colon (21.3 ± 3.1 cells per ×10 visual field) and rectum (13.7 ± 3.1 
cells). Similarly, there were no differences in the number of mast 
Figure 1
Proteolytic activity in human colonic biopsies and present in colonic 
washes. Arginine-directed protease activity in supernatants of biopsy 
from controls (black squares), IBS patients (IBS-D: D, circles; IBS-C: 
C, white squares; or IBS-D/C: D/C, diamonds), IBD patients (ulcerative 
colitis [UC]: black triangles; Crohn disease [CD]: x’s) or in IBS biopsy 
supernatants preincubated with the serine protease inhibitor FUT-175 
or supernatants from biopsies incubated with the NF-κB inhibitor BAY 
11-7085. IBS biopsy supernatants were separated according to the 
presence (I) or not (NI) of inflammatory signs, and biopsies were har-
vested at the level of the ascending colon (A) or the rectum (B). All 
+ FUT, all IBS patient supernatants (I and NI) incubated in the pres-
ence of FUT-175. (C) Protease activity in colonic washes from control 
(black squares) and IBS patients. Data are mean ± SEM. *P < 0.05, 
**P < 0.01, ***P < 0.005 compared with control group. 
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cells in control patients (20.9 ± 8.6, rectum; 20.3 ± 8.9, ascending 
colon), and there were no differences between IBS patients and 
controls (Figure 3, E and F).
The levels of protease inhibitor α-1-antiproteinase expression are 
unchanged in IBS and control patient biopsy supernatants, and entero-
kinase is detected only in IBS patient biopsy supernatants. The protein 
expression level of α-1-antiproteinase (a trypsin, tryptase, and neu-
trophil elastase inhibitor) was evaluated in supernatants from IBS 
or control biopsies by Western blot analysis and subsequent gel 
densitometry. The mean expression of α-1-antiproteinase was not 
significantly different in supernatants of IBS biopsies compared 
with supernatants of control biopsies (268 × 103 ± 39 × 103 pixels 
versus 282 × 103 ± 40 × 103 pixels; n = 10 in each group).
The expression of enterokinase, which converts trypsinogen to 
trypsin (18) was also investigated in the supernatants from IBS or 
control biopsies by Western blot analysis. The presence of entero-
kinase was detected in only 2 of 10 supernatants from IBS patient 
biopsies but in none of the supernatants from control patient 
biopsies (data not shown).
IBS tissue supernatants activate sensory neurons: a protease and PAR2-
dependent effect. To determine whether biopsies express media-
tors that can signal to sensory nerves, we examined the effects 
of biopsy supernatants on calcium mobilization of mouse dor-
sal root ganglion (DRG) neurons in culture. All supernatants 
from IBS biopsies induced a prompt increase in [Ca2+]i that was 
significantly higher than the signal caused by control patient 
supernatants (Figure 4). Supernatants from all the subgroups of 
IBS patients (IBS-D, IBS-C, IBS-D/C, or those with microscopic 
inflammation) evoked a similar increase in [Ca2+]i compared with 
supernatants from healthy control patients (Figure 4). Similarly, 
increased responses of sensory neurons to IBS biopsy superna-
tants was observed whether biopsy supernatants were taken from 
the ascending colon (Figure 4A) or the rectum (Figure 4B).
In order to assess whether the response was due to proteolytic 
activity in the supernatants, we repeated the experiments from 
the IBS patients in the presence of the broad-spectrum serine-
protease inhibitor FUT-175. The addition of FUT-175 to biopsy 
supernatants abolished the effects of IBS supernatants on [Ca2+]i 
in DRG neurons (Figure 4). Purified human trypsin and tryptase 
were also able to activate calcium mobilization in those cells, and 
this effect was blocked by FUT-175 (data not shown). In order to 
address the mechanism of biopsy supernatant-induced calcium 
mobilization, we isolated DRG neurons from mice lacking PAR2, 
as previous studies showed that PAR2 can play an important role 
in calcium signaling in response to proteases. We observed no 
increase in calcium mobilization in DRG neurons isolated from 
PAR2-deficient (PAR2–/–) mice and exposed to IBS biopsy superna-
tants (Figure 4). Taken together, these results show that proteases 
released by colonic tissues of IBS patients can signal to sensory 
neurons by activating PAR2.
IBS patient tissue supernatants cause thermal and mechanical hyperal-
gesia and allodynia in mice. Intraplantar administration of superna-
tants from IBS patients in mice decreased the withdrawal latency 
in response to thermal stimulus (Figure 5A), characteristic of 
thermal hyperalgesia, while supernatants from control patients 
had no effect. Similarly, IBS but not control patient biopsy super-
natants injected into the mouse paw provoked a significant 
increase in nociceptive score in response to mechanical stimula-
tion with von Frey filaments of various sizes (Figure 5, B–D). An 
increased nociceptive score was observed in response to innocu-
ous stimulus (smallest filament: 3.61) in mice that had received 
in the paw supernatants from IBS patients, while a score of 0 was 
observed for all other groups (Figure 5B). This demonstrates that 
IBS supernatants caused allodynia. In response to noxious stim-
ulus (larger filaments: 3.84 and 4.08), an increased nociceptive 
score was observed in IBS-injected mice compared with control 
supernatant–injected mice, demonstrating mechanical hyper-
algesia. When injected into the paw of PAR2–/– mice, IBS patient 
biopsy supernatants did not affect withdrawal latency (Figure 5A) 
or nociceptive score (Figure 5, B–D). These results point to a role 
for PAR2 activation in IBS patient biopsy supernatant–induced 
thermal and mechanical somatic hyperalgesia.
IBS tissue supernatants cause visceral hypersensitivity in mice: a protease 
and PAR2-dependent effect. Intracolonic administration of super-
natants from IBS patients increased the intensity of abdominal 
contractions in response to colorectal distension (Figure 6, A–C). 
From 6 to 12 hours after intracolonic administration of superna-
tants from IBS patients, the intensity of abdominal contractions 
Figure 2
Tryptase and trypsin expression in human colonic biopsies and cul-
ture supernatants. (A) Dual RT-PCR of tryptase and GADPH mRNA 
and of trypsin and gusb from IBS and control patient biopsies quanti-
fied by densitometry analysis of the gels. (B) Western blots of trypsin 
and tryptase proteins from control, IBS, or IBD patient biopsy super-
natants (top panel), quantified by densitometry analysis of the blots 
(bottom panel). Data are mean ± SEM; n = 12. *P < 0.05 compared 
with control group; **P < 0.01. 
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in response to different pressures of colorectal distension (15–60 
mmHg) was significantly increased compared with values measured 
before the intracolonic treatment (time 0) (Figure 6B). Increased 
intensity of abdominal contractions after IBS supernatant treat-
ment was observed in response to innocuous (15 mmHg) or nox-
ious (30–60 mmHg) stimuli, demonstrating the occurrence of both 
allodynia and hyperalgesia. In contrast, mice that had received 
intracolonic treatments with supernatants from control patients 
demonstrated levels of abdominal contraction response similar to 
those observed before the intracolonic administration (Figure 6C, 
far-left panel, triangles). When the protease inhibitor FUT-175 was 
added to biopsy supernatants from IBS patients, those superna-
tants did not elicit the colorectal distension–induced increase in 
abdominal contractions (Figure 6C, second panel). PAR2–/– mice, or 
mice treated with a PAR2 antagonist (19), did not demonstrate IBS 
supernatant–induced increases in abdominal contractions com-
pared with basal distension (before intracolonic administration) 
(Figure 6C, third and fourth panels, respectively).
Supernatants from all the subgroups of IBS patients (IBS-D, 
IBS-C, IBS-D/C, and those with microscopic inflammation) 
evoked a similar increase in the intensity of abdominal contrac-
tion in response to colorectal distension at all pressures compared 
with control distension (before intracolonic administration of 
supernatant) (Figure 7).
The results shown in Figures 6 and 7 were obtained using super-
natants from biopsies harvested from the ascending colon, but 
similar results were observed with supernatants of biopsies from 
the rectum (data not shown). Intracolonic administration of 0.5 U 
of trypsin (100 μl) increased the intensity of abdominal contrac-
tion in response to colorectal distension at all pressures (Figure 8). 
However, this increase was not observed after the administra-
tion of 0.2 U of trypsin (Figure 8). Interestingly, 0.52 U of trypsin 
corresponds to the average proteolytic activity released from IBS 
biopsies and present in 100 μl of supernatants that were injected 
to mice. 0.2 U of trypsin corresponds to the average proteolytic 
activity in control biopsies (Figure 8).
Discussion
We show that proteolytic at an arginine site is released in sig-
nificantly higher amounts from colonic biopsies of IBS and IBD 
patients compared with controls. Moreover, proteolytic activity 
released in vivo in the lumen of IBS patients in significantly higher 
quantities than in controls. Further, we show that this proteolytic 
activity is responsible for activation of sensory neurons, as well 
as generation of somatic hyperalgesia and visceral hypersensitiv-
ity, through a mechanism involving the activation of PAR2. These 
results are in accordance with the concept that PAR2 represents an 
important receptor mediating the symptoms of IBS (20). Thus, 
PAR2 activation modifies intestinal chloride secretion, consistent 
with a role for this receptor in IBS-associated secretory dysfunc-
tions (21–24). PAR2 agonists evoke an increase in intestinal barrier 
permeability (25, 26), which is known to be associated with IBS 
symptoms in some patients (27, 28) as well as in animal models 
(29). PAR2 activation in the colon of mice induces signs of inflam-
mation (20, 25), while the putative role for microinflammation in 
tissues of IBS patients is now widely recognized (5–7). PAR2 acti-
vation also modifies gastrointestinal motility patterns in vivo and 
in vitro (30–32). But the strongest evidence for a role for PAR2 in 
generation of IBS symptoms relies on the effects of PAR2 activa-
tion on visceral nociceptive functions. It has been established that 
PAR2 agonists evoke long-lasting visceral hypersensitivity (12) and 
hyperexcitability of enteric neurons (33, 34). In the present study, 
we shed light on the role of PAR2 in human pathophysiology, dem-
onstrating that proteases that can signal through PAR2 are specifi-
Figure 3
Tryptase immunoreactivity in rectal biopsies from control (A, D, and E) 
and IBS patients (B, C, and F). Tryptase was mostly localized to cells 
found throughout the lamina propria (A–C) and around the base of 
rectal mucosal crypts (C). Some cells (e.g., C), had obvious processes 
at either the apical and/or basal poles, and often these cells displayed 
intense immunoreactivity compared with neighboring cells (images in 
B and C were taken under identical exposure conditions and reflect dif-
ferences in intensity). Occasional tryptase-immunoreactive cells were 
found in the epithelium of both control (D) and IBS patients; these 
had the appearance of enteroendocrine cells, based on the obvious 
basolateral process. No differences were observed in the cell popula-
tions of IBS and control patients with respect to either the density of 
cells in rectal biopsies (G) or the intensity of immunoreactivity. Alcian 
blue–labeled mast cells in a control (E) and IBS patient (F). Note that 
the majority of tryptase-immunoreactive cells (e.g., B) have the size, 
shape, and cellular location of mast cells. Scale bars: 50 μm.
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cally released from colonic biopsies of IBS patients. Moreover, we 
show here that of all the mediators released from these biopsies, 
proteases play a major role in signaling to sensory nerves and in 
the generation of visceral hypersensitivity, since the serine-protease 
inhibitor FUT-175 abolished calcium mobilization in mouse DRG 
neurons and signs of visceral pain. The use of PAR2–/– mice and a 
PAR2 antagonist clearly revealed that these responses are dependent 
on the activation of PAR2. We have also observed increased proteo-
lytic activity in biopsies from IBD patients. PAR2, which is known 
to mediate the proinflammatory effects of trypsin and tryptase 
(35), is also overexpressed in tissues from IBD patients (36). This 
suggests that PAR2 could be a common target in the treatment of 
IBD and IBS. The fact that proteolytic activity is increased in both 
IBS and IBD patient biopsy supernatants demonstrates that high 
proteolytic activity is not specifically associated with IBS but is 
also involved in other gastrointestinal pathologies. However, the 
increased trypsin expression seems to be specific to IBS, as it was 
not observed in IBD biopsy supernatants.
Among the mediators that are present and potentially released 
from tissues of IBS patients, it was surprising to see that proteases 
accounted for almost all of the pronociceptive effects of IBS biop-
sy supernatants: hyperalgesia, allodynia, and the calcium flux in 
sensory neurons were abolished by protease inhibitor FUT-175. 
Other mediators, such as 5-hydroxytryptamine (5-HT), histamine, 
ATP, or prostaglandins, which are likely to be present and released 
by mucosal biopsies, can signal to sensory nerves and have been 
shown to induce visceral hypersensitivity (37, 38). One possible 
explanation for these data is that proteases are less susceptible to 
degradation than other mediators in our experimental conditions 
of incubation and therefore account for most of the pronocicep-
tive effects. However, it may also be hypothesized that proteases 
play a pivotal role in sensitization of sensory nerves to other pro-
nociceptive mediators. This hypothesis is consistent with the find-
ing that activation of the calcium channel TRPV1 is potentiated by 
preexposure to PAR2-activating proteases (39, 40).
The question of the nature of the proteases that are specifically 
released from IBS patient biopsies is essential to the identification 
of potential new targets for the treatment of IBS. Our results show 
that the proteases tryptase and trypsin, both of which can activate 
PAR2, are upregulated and released into biopsy supernatants. This is 
in agreement with previous results that have demonstrated that the 
mucosal content of tryptase was increased in IBS patients and that 
the number of degranulating mast cells was increased by 150% in 
the same patients (41). In our study, we did not observe an increase 
in the number of mast cells present in the biopsies from controls or 
IBS patients, but we detected a significant increase in the amount 
of tryptase released in IBS compared with control biopsy superna-
tants. This suggests, like the study by Barbara et al. (41, 42), that 
although higher mast cell numbers might not be present in tissues, 
more mast cells are actively degranulating in tissues of IBS patients. 
Other studies, such as that by Weston et al., have shown an increase 
in mast cell numbers in ileal tissues of IBS compared with control 
patients (43). Several reasons could be given to explain the discrep-
ancies among all the studies on mast cell numbers in IBS patient 
biopsies, including the counting methods, the nature of the biop-
sies and the regions of the gut that were sampled, and the detec-
tion methods employed. The overall conclusion of all those studies 
is that mast cell mediators, and particularly tryptase, are released 
in significantly higher amounts in the tissues of IBS patients. In 
their study, Barbara et al. demonstrated that in IBS patients, mast 
cells lie closer to nerve fibers of the mucosa compared with those in 
control patients (42). This suggests that once released by degranu-
lating mast cells, tryptase could be in direct contact with enteric or 
primary afferent nerves, both of which express PAR2 (5–7, 33, 44, 
45), and induce hyperexcitability (34, 45).
Nonpancreatic trypsin can be released from different cell types 
of the gut, including endothelial cells, and epithelial cells (46). In 
a recent report, we demonstrated that upon bacterial infection, 
colonic tissues from the infected mouse host were able to express 
significant amounts of trypsin, which then participated in the 
generation of an inflammatory response through the activation of 
PAR2 (47). Therefore, both trypsin and tryptase can be considered 
as the proteases released from IBS patient tissues that are respon-
sible for PAR2 activation. Cells that produce tryptase (mostly mast 
cells) and trypsin (endothelial and/or epithelial cells) could act as 
effectors that release their mediators (proteases), which then gen-
erate action potential in enteric and primary afferent nerve end-
ings within the lamina propria, leading to enteric neuron hyper-
excitability and visceral hyperalgesia. It is interesting to note that 
Figure 4
Calcium mobilization in sensory neurons exposed to human colonic 
biopsy supernatants. Calcium flux in sensory neurons from wild-type 
(PAR2+/+) and PAR2–/– mice exposed to supernatants of biopsies from 
control and IBS patients or biopsy supernatants preincubated with a 
serine protease inhibitor (FUT-175). IBS patient supernatants were 
either regrouped together (all supernatants [All]) or divided into sub-
groups. Biopsies were collected either from the ascending colon (A) or 
the rectum (B). Data are mean ± SEM. *P < 0.05 compared with con-
trol group; †P < 0.05 compared with the group with all IBS supernatants 
tested in PAR2+/+ neurons.
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the amount of proteolytic activity in IBS patient biopsies, when 
compared to the activity of known concentrations of trypsin, is 
perfectly within the range of trypsin concentrations that are nec-
essary to activate PAR2 on sensory neurons (48). Moreover, the 
dose of trypsin (0.2 U) that corresponds to the average proteolytic 
activity in control biopsies had no effect on colonic sensitivity to 
colorectal distension. In contrast, doses of trypsin that correspond 
to the proteolytic activity released by IBS biopsies provoked allo-
dynia and visceral hyperalgesia (Figure 8). Why IBS should be asso-
ciated with increased proteolytic activity in the intestinal mucosa 
remains to be clarified. Another possible source of proteases could 
be the luminal microflora. Several studies have suggested that bac-
terial flora is different in IBS and control patients (49, 50). Our 
study shows that trypsin and tryptase transcription in IBS patient 
tissues is increased, suggesting that those proteases are at least 
in part responsible for the IBS-associated increased proteolytic 
activity. However, we cannot rule out the possibility that bacte-
rial serine proteases could also be partly responsible for increased 
mucosal proteolytic activity. Further studies could investigate 
proteolytic activity in tissues of patients receiving treatments that 
would affect their microflora (probiotic or antibiotic treatments) 
or their pancreatic enzyme secretion (atropine treatments).
We observed that the expression of α-1-antiproteinase, one of 
the most studied inhibitors of trypsin, tryptase, and neutrophil 
elastase, was not different in supernatants of biopsies from control 
and IBS patients. This finding, although limited to one member 
of the serpin family, argues against the hypothesis that decreased 
expression of protease inhibitor could allow increased proteolytic 
activity at mucosal surfaces of IBS patients. The presence of entero-
kinase in supernatants of some IBS patient biopsies suggests that 
pro-forms of enzymes, in particular trypsinogen, could be more 
effectively cleaved into active enzymes in tissues of IBS patients. 
However, the proportion of IBS patient tissues that express entero-
kinase is relatively small (2 of 10 patients), suggesting that the 
presence of enterokinase in IBS patient tissues could not be the 
sole mechanism to explain IBS-associated increased activation of 
proteases. Finally, we have observed that incubation of biopsies 
in the presence of a specific NF-κB inhibitor (14) significantly 
decreased the proteolytic activity released by IBS but not control 
patient biopsies (Figure 1, A and B). This result could suggest that 
NF-κB–dependent transcription of proteases is increased in IBS 
patient tissues. In fact, trypsin and tryptase mRNA levels were sig-
nificantly increased in IBS patient biopsies (Figure 2). Although 
several studies demonstrated that arginine-directed proteases can 
activate NF-κB (51–54), the regulation of serine protease secretion 
by NF-κB is not as well documented. Therefore, our study also 
suggests that arginine-directed protease expression and activity, 
as has been demonstrated for matrix metalloproteinases (55–57), 
depends on NF-κB DNA binding.
In the visceral hypersensitivity experiments, IBS patient biopsy 
supernatants induced hyperalgesia and allodynia only several 
hours (6 hours; Figure 6A) after intracolonic administration. In 
Figure 5
Somatic nociception of mice in response to injection of human colonic biopsy supernatants into paws. Graph of withdrawal latency (A) and noci-
ceptive scores (B–D) in response to thermal (plantar test) or mechanical (von Frey filaments) stimulation, respectively, of mouse paws that had 
received an injection of control or IBS patient biopsy supernatants or saline solution. Wild-type mice (PAR2+/+: squares [A], black bars [B–D]) and 
PAR2-deficient mice (PAR2–/–: x’s [A], gray bars [B–D]) had received intraplantar injections. Three sizes of von Frey filaments were used: filament 
3.61 (B), filament 3.84 (C), and filament 4.08 (D). All biopsies represented in this figure were collected from the rectum; n = 8 for controls; n = 9 
for IBS. Data are mean ± SEM for withdrawal latencies and median and range (in brackets) for mechanical stimuli testing (von Frey filaments). 
*P < 0.05 compared with basal measures (before the intraplantar injection: time 0).
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contrast, the effects of the same supernatants on calcium signaling 
in DRG neurons were observed within seconds, and the pronoci-
ceptive effects in the paw (Figure 5) were significant before the first 
hour. This delay in the appearance of visceral hyperalgesia but not 
somatic hyperalgesia could be explained by the mode of adminis-
tration of the supernatants. Intraluminal administration requires 
that the mediators penetrate the tissues, crossing the epithelial 
barrier, which might delay the effects of those mediators on pri-
mary afferents. It has been established that intracolonic adminis-
tration of PAR2 agonists caused a breakdown in the integrity of the 
intestinal barrier (25, 26). Therefore, the action of PAR2-activating 
proteases administered in the mouse colonic lumen in the setting 
Figure 6
Visceral sensitivity in response to human colonic biopsy supernatants. Recordings of mouse abdominal muscle contraction in response to 
colorectal distension before (control) or 6 hours after intracolonic administration of ascending colon biopsy supernatants from IBS patients (A 
and B) or control patients (filled triangles in C). (A) Representative traces of mouse abdominal muscle contractions in response to 60 mmHg 
colorectal distension, in PAR2+/+ or PAR2–/– mice before (control) or after intracolonic (i.c.) administration of IBS ascending colon biopsy super-
natant alone or in combination with the protease inhibitor FUT or a PAR2 antagonist. (B) Abdominal contraction responses to different pres-
sures of distension (15–60 mmHg) before (time 0) or after intracolonic administration of IBS patient ascending colon biopsy supernatants. Data 
are mean ± SEM; n = 8. *P < 0.05, **P < 0.01, ***P < 0.005 compared with basal (time 0) measurements. (C) Mouse abdominal contraction 
response to increasing pressures of distension in PAR2+/+ or PAR2–/– mice before (control distension) or 6 hours after intracolonic administration 
of IBS biopsy supernatants (filled squares) alone or in combination with the protease inhibitor FUT or a PAR2 antagonist or after the intracolonic 
administration of biopsy supernatants from control patients (filled triangles). Data are mean ± SEM; n = 12 for the biopsy supernatants from 
control patients; n = 18 for IBS biopsy supernatants. *P < 0.05, **P < 0.01, ***P < 0.005 compared with control distension. For all data in this 
figure, biopsies were collected from the ascending colon.
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of visceral hypersensitivity might be primarily on intestinal perme-
ability and then secondarily on primary afferent nerves.
Similar calcium signals in DRG neurons (Figure 4) and visceral 
hypersensitivity responses (Figure 7) were observed whether the 
biopsies were collected from IBS-D, IBS-C, or IBS-D/C patients. 
Moreover, the presence of microscopic inflammation in some 
IBS patients did not modify the responses observed in vivo or in 
vitro. We did not expect to find a common pattern of responses 
in these tissues that would suggest common mediators (proteases 
and PAR2) in all IBS patients, despite the variability in clinical 
presentation. Whether PAR2 and proteases contribute to altered 
bowel frequency and stool consistency is not known, but the fact 
that PAR2 activation leads to changes in intrinsic and extrinsic 
primary afferents (33, 34, 45, 58) is not inconsistent with these 
findings, since alterations in sensory processing in the gut wall 
could just as easily lead to enhanced as reduced motility, for 
example. Since similar findings for PAR2 and proteolytic activity 
were observed regardless of the IBS subtype, we cannot exclude 
the possibility that PAR2 activation and protease release could be a 
feature common to all colonic pathologies associated with hyper-
algesia. However, our results strongly suggest a common function 
for PAR2-activating proteases on a clinical feature reported in all 
IBS patients: visceral hypersensitivity. Importantly, our results 
highlight PAR2-activating proteases and PAR2 as potential com-
mon therapeutic targets in all IBS patients for the 
treatment of abdominal pain.
Methods
Patients and biopsies. Patients with IBS, as defined by the 
Rome II criteria (59, 60), undergoing clinical evaluation 
at the University of Calgary gastrointestinal (GI) clinic 
were invited to participate in the study (Tables 1 and 2). 
Patients with confirmed diagnosis of celiac disease, infec-
tious colitis, endocrine or CNS disorders, or GI malig-
nancy were excluded. IBD patients with a confirmed 
diagnosis of Crohn disease or ulcerative colitis who were 
undergoing colonoscopy for assessment of disease activ-
ity were also invited to participate. Individuals undergo-
ing colorectal cancer screening had tissue samples col-
lected during colonoscopy and were considered controls 
(see Tables 1 and 2). The University of Calgary Conjoint 
Ethics Committee approved the human research protocol. Written and 
verbal informed consent was obtained prior to enrollment in the study, 
according to the Declaration of Helsinki. The colonoscopic procedure 
employed a standard bowel preparation with an osmotic lavage (polyethyl-
ene glycol in the form of Colyte; GlaxoSmithKline), 3 days of clear fluids, 
and an overnight fast. To achieve conscious sedation, the narcotic fentanyl 
(Sublimaze; Abbott) and a benzodiazepine, diazepam in lipid emulsion 
(Diazemuls; Pfizer) or midazolam (Versed; Novopharm Ltd.), were admin-
istered intravenously. All colonic biopsies were collected during intubation 
of the colon and were taken first from the rectum (to avoid any artifact of 
intubation trauma) and then from the ascending colon.
Eight biopsies (10–20 mg) were collected from each control, IBS patient, 
or IBD patient: 4 biopsies from the rectum and 4 from the ascending colon. 
Fresh biopsies were rinsed in saline and incubated immediately in 2 ml of 
HBSS at 37°C for 1 hour. Biopsies of the second group of patients (Table 2) 
Figure 7
Visceral sensitivity in response to human colonic 
biopsy supernatants from different IBS patient sub-
groups. Abdominal muscle contraction responses of 
mice before (white bars) and 6 hours after intraco-
lonic administration of IBS ascending colon biopsy 
supernatant (gray bars). Results were analyzed in 
different subgroups: IBS-C, IBS-D, IBS-D/C, inflam-
mation, and no inflammation. Data are mean ± SEM. 
*P < 0.05 compared with control distension.
Figure 8
Visceral sensitivity in response to different doses of trypsin. Abdomi-
nal contraction response of mice 6 hours after intracolonic adminis-
tration of trypsin (0.2, 0.5, and 1.0 U of trypsin) or its vehicle (saline) 
in response to different pressures of distension (15–60 mmHg). Data 
are mean ± SEM; n = 8 per dose of trypsin. *P < 0.05, **P < 0.01, 
***P < 0.005 compared with control distension (time 0).
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were incubated in 2 ml of HBSS at 37°C for 1 hour with a NF-κB inhibi-
tor, BAY 11-7085 (20 μM; BIOMOL) (14). For all experiments, supernatant 
volumes were standardized to the weight of incubated biopsies and not to 
supernatant protein, as protein content was below the detection thresh-
old in biopsy supernatants. After incubation, biopsies were snap frozen 
in TRIzol (Invitrogen) for further RT-PCR analysis. Other biopsies not 
used for incubations were fixed in Zamboni’s solution overnight at 4°C 
for analyses of mast cells and tryptase immunoreactivity. Separate biopsies 
were obtained for routine histopathology performed by a histopathologist 
blinded to the patient’s inclusion in the study. For the IBS patients, clas-
sification of inflamed versus noninflamed tissues was based on the report 
of the histopathologist on the presence of lymphocyte/plasma cell infil-
tration and architectural distortion, as described in Tables 1 and 2. This 
overlap between IBS and microscopic colitis is consistent with previously 
reported population-based studies of IBS patients (61). For IBD patients, 
histological evidence of IBD was also determined by a histopathologist.
Colonic washes were performed by instillation of 30 ml of a saline solu-
tion (0.9% NaCl), though the endoscope, into the patient’s rectum (Table 2). 
The saline solution was left in the rectum lumen for 30 seconds and was 
then aspirated, filtered with a 0.2-μm syringe filter (Acrodisc; Pall Corp.), 
and frozen. Collection of biopsies from these patients was performed as 
described above from nonwashed mucosa.
Proteinase activity assay. Trypsin-like activity was determined using a Fluo-
roskan Ascent microplate fluorometer (Thermo Scientific) as previously 
described (47) (excitation, 355 nm; emission, 460 nm). The hydrolysis rate 
was measured at room temperature over a 20-minute period following 
addition of a biopsy supernatant sample (5 μl) or colonic washes (5 μl) 
to 200 μl of substrate solution (Boc-Gln-Ala-Arg- AMC [75 μM] in Tris 
[50 μM], CaCl2 [20 μM] buffer, pH 7.4) and was standardized to the rate 
generated by known concentrations of trypsin and normalized as described 
above to the weight of the biopsy. The proteolytic activity of the colonic 
washes was normalized to the protein concentration determined with a 
Micro BCA Protein Assay Kit (Pierce Biotechnologies). FUT-175 was added 
to biopsy supernatants at a final concentration of 50 μg/ml.
RT-PCR for trypsin and tryptase. Upon thawing, biopsies were homogenized 
in TRIzol and RNA extracted according to the manufacturer’s guidelines. 
For trypsin, RNA was quantified and 2 μg reverse transcribed using Taq-
Man reverse transcription reagents (Applied Biosystems) according to the 
manufacturer’s instructions. The PCR reaction was sampled at 15, 20, 25, 
30, and 35 cycles. Only at 30 cycles could products be seen for both trypsin 
and the β-glucuronidase (gusb) control. This cycle number was used for 
quantification of all samples. The trypsin/gusb 
mRNA ratio was calculated for each patient 
and then normalized to the average of the 
control patients. Primers used were as follows: 
trypsin, 382-bp product (forward 5'-CGCGT-
GTCCACCATCTCTCTGC-3' and reverse 
5'-TTAGCTGTTGGCAGCTATGGTG-3') and 
gusb 81-bp product (forward 5'-CTCATTT-
GGAATTTTGCCGATT-3' and reverse 
5'-CCGAGTGAAGATCCCCTTTTTA-3'). 
Cycling conditions were 94°C for 10 min-
utes, followed by 94°C for 30 seconds, 60°C 
for 30 seconds, and 72°C for 30 seconds for 
30 cycles. Product identity was confirmed 
by sequencing. For tryptase, the PCR reac-
tion was performed using a dual quantitative 
RT-PCR kit (Maxim Biotech Inc.). Two micro-
liters of cDNA product was amplified in a final 
concentration of 35 μl of Master Mixture con-
taining dNTPs and the primers for tryptase and GADPH (Maxim Biotech 
Inc.), and 1 U of Taq polymerase (Maxim Biotech Inc.) in a total volume 
of 50 μl. For each sample, GADPH was coamplified as an internal control 
of tryptase amplification. Aliquots of PCR reactions (approximately 20 μl) 
were normalized to the equivalent signals from the GADPH mRNA and 
separated by electrophoresis through 1% agarose gels containing 0.2 μg/ml 
ethidium bromide. Gels were photographed and analyzed by densitometry 
using Bio-Rad imaging software Quantity One 4.6.2. Tryptase mRNA 
expression is presented as a ratio to GADPH.
Western blotting for trypsin, tryptase, α-1-antiproteinase, and enterokinase. 
Proteins were precipitated from biopsy supernatants with 10% TCA and 
resuspended with 30 μl of HBSS (Sigma-Aldrich) and 30 μl of Laemmli 
sample loading buffer (Sigma-Aldrich). Equal amounts (standardized 
according to biopsy tissue weight) of each supernatant were subjected to 
10% SDS-PAGE and then electrotransferred onto a 0.45-mm nitrocellu-
lose membrane. Membranes were blocked with Tris-buffered saline with 
5% milk blocking solution and then incubated overnight at 4°C with the 
primary antibodies. We used a 1/5,000 dilution for the trypsin antibody 
(Chemicon International), 1/1,000 for the tryptase antibody (Chemicon 
International), 1/1,000 for the α-1-antiproteinase antibody (Cedarlane 
Laboratories Ltd.), and 2.5 μg/ml for the anti-enterokinase antibody (R&D 
Table 1
Characteristics of patients from which biopsies were collected for culture media incubations
Characteristic	 Control	(n	=	12)	 IBS	(n	=	18)	 IBD	(n	=	5,	4	UC,	1	CD)
Age (yr, range) 52 (34–70) 44 (20–69) 51 (17–79)
Sex (no., F/M) 8/4 16/2 2/3
Bowel movements
 Diarrhea 1A 9 0
 Constipation 1A 4 0
 Alternating diarrhea/constipation 0 5 0
History of intestinal infection 0 1 0
Signs of inflammation 0 7B 1 moderate,  
    3 moderate/severe,  
    1 severe
Values are number of patients with characteristic unless otherwise indicated. AAcute episodes with no 
clinical evidence of IBS. BLymphocyte/plasma cell infiltration without crypt abscess; architectural dis-
tortion such as mucosal edema, superficial erosions, and crypt branching. CD, Crohn disease;  
UC, ulcerative colitis.
Table 2
Characteristics of patients from which rectal lavages and/or 
biopsies were collected for proteolytic activity assessment and 
incubations with the NF-κB inhibitor BAY 11-7085
Characteristic	 Control	(n	=	10)	 IBS	(n	=	9)
Age (yr, range) 46 (31–63) 43 (22–58)
Sex (no., F/M) 7/3 8/1
Bowel movements
 Diarrhea 0 4A
 Constipation 0 2
 Alternating diarrhea/constipation 0 3A
History of intestinal infection 0 0
Signs of inflammationB 0 1B
Values are number of patients with characteristic unless otherwise 
indicated. AOne patient in each of these subgroups refused the biopsies 
and accepted the colonic wash. BLymphocyte/plasma cell infiltration 
without crypt abscess; architectural distortion such as mucosal edema, 
superficial erosions, and crypt branching.
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Systems). After washing, a secondary antibody (Jackson ImmunoResearch 
Laboratories Inc.) diluted 1/50,000 for trypsin and tryptase, 1/20,000 for 
enterokinase (donkey anti-mouse IgG or AffiniPure donkey anti-goat), or 
1/20,000 for α-1-antitrypsin was added for 1 hour at room temperature. 
The membrane was incubated for 1–5 minutes with ECL-WB detection 
reagents (Amersham Biosciences). Films were scanned and the bands ana-
lyzed by densitometry using Bio-Rad imaging software Quantity One 4.6.2. 
Tryptase and trypsin protein amounts were expressed in pixels, representa-
tive of the optic density of detected bands.
Mast cells and tryptase immunoreactivity. Biopsy samples were fixed by 
immersion in Zamboni’s fixative overnight at 4°C. After washing in PBS, 
they were cryoprotected in PBS containing 20% sucrose. Sections were cut 
on a cryostat (12 μm) and mounted on polylysine-coated slides. Sections 
were then rinsed in 0.125 N HCl and stained with Alcian blue (1% Alcian 
blue [BDH Chemicals Ltd.] in 0.7 N HCl) for 60 minutes at room tem-
perature. They were differentiated in 0.125 N HCl and washed in distilled 
water, dehydrated, and mounted. Blue-stained mucosal mast cells were 
counted using a Zeiss Axioplan microscope, and data are presented as cells 
per ×10 objective field by an observer blinded to the patient groups. Data 
are presented as mean ± SEM. Statistical comparison was made using a 
Mann-Whitney U test.
For the assessment of tryptase immunoreactivity, sections were incubat-
ed for 48 hours at 4°C in primary mouse anti-human tryptase monoclonal 
(clone G3, 1:1,000; Chemicon International; Millipore) (17). After incuba-
tion, sections were washed 3 time in PBS containing 0.1% Triton X-100 
and incubated in secondary donkey anti-mouse conjugated to CY3 (1:100; 
Jackson ImmunoResearch Laboratories Inc.) for 1 hour at room temper-
ature. They were then washed again as described above and mounted in 
bicarbonate-buffered glycerol. Immunoreactive cells were counted using a 
Zeiss Axioplan microscope, and data are presented as cells per ×40 objec-
tive field by an observer blinded to the patient groups. Cells were counted 
in 3 random, nonoverlapping fields in 3 sections per patient in the lamina 
propria and epithelium, only if they displayed a prominent unlabeled 
nucleus. No cell fragments were included in the counts. In some sections, 
it was apparent that immunoreactivity was associated with degranulating 
mast cells. We did not count the degree of degranulation, since quantifica-
tion of noncellular immunoreactivity was not readily accomplished. Cell 
counts were compared with a Mann-Whitney U test.
Animals. Male C57BL/6 mice (6–8 weeks old) were obtained from Charles 
River Laboratories, and PAR2–/– mice originally from Johnson & Johnson 
Research Pharmaceutical together with wild-type littermates were bred at 
the University of Calgary Animal Care facility. Mice were housed in trans-
parent plastic cages with free access to food and water, in rooms with a 
12-hour light/12-hour dark cycle. All experiments were approved by the 
Animal Care Committee of the University of Calgary and were performed 
in accordance with the guidelines of the Canadian Council on Animal 
Care. Mice were used for somatic and visceral nociception experiments, as 
well as for DRG neuron isolation.
Ca2+ imaging in sensory neurons. DRGs were rinsed in cold DMEM and 
incubated in DMEM containing 0.5 mg/ml trypsin, 1 mg/ml collagenase, 
and 0.1 mg/ml DNAse I (all from Sigma-Aldrich) for 45–60 minutes at 
37°C (39, 48). Soybean trypsin inhibitor (SBTI) (Sigma-Aldrich) was added 
to neutralize trypsin, and the suspension was centrifuged at about 1,000 g 
for 1 minute. Neurons in the pellet were suspended in DMEM containing 
10% FBS, 2 mM glutamine, 1 mg/ml penicillin/streptomycin, and DNAse I 
(all from Sigma-Aldrich). Cells were plated in Matrigel-treated glass-bot-
tom Petri dishes (35-mm diameter; MatTek Corp.) and recovered with the 
complete culture media (described above). Calcium assay was performed 
72 hours later after visual inspection of the cells, as previously described 
(39, 48). The Petri dishes were washed twice with HBSS pH 7.4 supple-
mented with 0.1% BSA. The cells were then incubated for 45–60 minutes 
at 37°C in the same solution to which 3–5 μM of Fluo3-AM (Invitrogen) 
was added. After the incubation, the Petri dishes were washed twice again 
with the assay buffer (280 mM CaCl2, 150 mM NaCl, 20 mM HEPES, 10 
mM dextrose, 3 mM KCl, 250 μM sulfinpyrazone, pH 7.4), of which 2 ml 
was left in each Petri dish. Cells were observed using a Wide-Field Fluo-
rescence Olympus IX-70 Microscope and an LCPlan FL ×40 objective. A 
kinetic of 30 pictures in 90 seconds was performed: neurons were exposed 
to control or IBS biopsy supernatant (100 μl) after the fifth picture; the 
first 5 pictures were used to determine the baseline by fluorescence mea-
surement at 460–490 nm excitation and 515 nm emission in individual 
cells, using the acquisition program OpenLab software (Agilent Tech-
nologies). The results were expressed as the ratio between the highest 
fluorescence measurement and the baseline. [Ca2+]i was calculated using 
the equation [Ca2+]i = Kd (F – Fmin)/(Fmax – F), where Kd is the dissociation 
constant of the Ca2+–fluo-3 complex (400 nM), and F represents the fluo-
rescence intensity of the cells expressed as the ratio between the highest 
fluorescence measurement and the baseline. Fmax represents the maximum 
fluorescence (obtained by treating cells with 10 μM calcium ionophore 
A23187), and Fmin corresponds to the minimum fluorescence (obtained 
from ionophore-treated cells in the presence of 3 mM EGTA). The fluo-
rescence intensities were expressed as the increase in fluorescence with 
respect to baseline fluorescence intensity before stimulation (62). The 
experiments were repeated 3 times per biopsy. In a second set of experi-
ments, neurons were treated with IBS supernatant preincubated for 10 
minutes with the serine protease inhibitor (FUT-175, 50 μg/ml).
Somatic nociception. Supernatants from IBS and control patient biopsy 
incubations or saline were injected into the mouse paw under light halo-
thane anesthesia and in a total volume of 25 μl. Nociceptive responses to 
thermal stimulation were evaluated by measuring withdrawal latency after 
exposure of the mouse paw to radiant heat stimulus applied by a plan-
tar test apparatus (Ugo Basile) (13). Nociceptive responses to mechanical 
stimulation were performed using von Frey monofilaments of different 
bending forces (0.07 g for the 3.61 filament, 0.692 g for the 3.84 filament, 
and 1.202 g for the 4.08 filament) as previously described (13, 63, 64). The 
minimum force required to elicit a reproducible withdrawal reflex on 3 
applications of the von Frey filament to the plantar surface of the hind-
paw was recorded as the mechanical nociceptive score. Scores were assigned 
based on the animal’s response: 0 = no movement; 1 = removal of the paw; 
2 = removal of the paw and vocalization or licking or holding of the paw. 
The score was expressed as a percentage of the maximal score for the 3 
applications. Median and range are represented for percentage of maxi-
mal nociceptive score. Thermal and mechanical nociceptive responses were 
measured in basal conditions (in naive animals before any treatment) and 
hourly after the intraplantar injections. Each supernatant was injected into 
the paw of 6 different mice, and the mean of the nociceptive responses for 
each supernatant is presented in Figure 5.
Colorectal distention and electromyography recording. Mice were anaesthetized 
by xylazine, ketamine, and saline (1:20:29 ratio, intraperitoneally). Three 
groups of electrodes (Bioflex insulated wire AS631; Cooner Wire) were 
implanted in the abdominal external oblique musculature. Electrodes were 
exteriorized at the back of the neck and protected by a plastic tube attached 
to the skin. Colorectal distension was performed 5 days after the electrode 
implantation, as previously described (65). Mice were placed in plastic tun-
nels (3-cm diameter, 10-cm length) in which they could not move, escape, 
or turn around. They were accustomed to this procedure for 1 day before 
rectal distension, to minimize stress reactions during experiments. The 
wires were connected to a Bio Amp (ADInstruments) itself connected to a 
PowerLab (ADInstruments) used as an electromyogram acquisition system 
using Chart 5 software (ADInstruments). Colorectal distension was then 
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performed in a stepwise fashion. The balloon (10.5-mm diameter) used for 
distensions was an arterial embolectomy probe (LeMaitre Embolectomy 
Catheter 4F; LeMaitre Vascular). Rectal distension was performed by inser-
tion of the balloon into the colon at 5 mm proximal to the rectum. The 
balloon was then inflated in a stepwise fashion from 0 to 60 mmHg in 
15-mmHg increments. Ten-second distensions were performed in tripli-
cate at pressures of 15, 30, 45, and 60 mmHg with 5-minute intervals. The 
balloon, connected to a manometer and a syringe, was filled with tepid 
water in order to avoid temperature contrast. To detect possible leakage, 
the volume of water introduced into the balloon was verified by complete 
removal at the end of the distension period.
Biopsy supernatants from control or IBS patients (100 μl) were admin-
istrated intracolonically to mice under light halothane anesthesia. At set 
times after biopsy sample administration (0, 3, 6, 10, and 24 hours), a 
series of rectal distentions were performed to generate a pressure-response 
curve. In a second set of experiments, 3 groups of 17 mice had identical 
intracolonic instillation of IBS supernatants, and colorectal distension 
was performed, once before the administration and again 6 hours after. 
The first group received the IBS biopsy supernatant preincubated with 
the serine protease inhibitor (FUT-175, 50 μg/ml) for 10 minutes before 
the intracolonic administration. The second group was pretreated with a 
PAR2 antagonist (4 mg/mouse; given intraperitoneally) 30 minutes before 
the intracolonic administration, as previously described (19). The PAR2 
antagonist was obtained from T. Hembrough (EntreMed Inc., Rockville, 
Maryland, USA), and its pharmacological characteristics were published 
in Kelso et al. (19). For the last group, PAR2–/– mice were used and the 
intracolonic administration of IBS biopsy supernatant was performed. In 
a last set of experiments, 4 groups of 10 mice were administrated intraco-
lonically 100 μl of trypsin (Sigma-Aldrich) at 0, 0.2, 0.5, and 1.0 U respec-
tively; colorectal distension was performed 6 hours after administration. 
The trypsin was dissolved in saline solution (0.9% sodium chloride).
Statistics. Data are presented as mean ± SEM except for nociceptive scores. 
Analyses were performed using GraphPad Prism 3.0 software. All data 
were normally distributed. Between-group comparisons were performed 
by Student’s unpaired 2-tailed t test. Multiple comparisons within groups 
were performed by repeated–measures 1-way ANOVA, followed by Tukey’s 
procedure. The Mann-Whitney U test was used for the comparison of noci-
ceptive scores in IBS-injected mice compared with control-injected mice. 
Statistical significance was accepted at P < 0.05.
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